MMP-15 is upregulated in preeclampsia, but does not cleave endoglin to produce soluble endoglin.
Preeclampsia is a major pregnancy complication, characterized by severe endothelial dysfunction, hypertension and maternal end-organ damage. Soluble endoglin is an anti-angiogenic protein released from placenta and thought to play a central role in causing the endothelial dysfunction and maternal or...
Main Authors: | Tu'uhevaha J Kaitu'u-Lino, Kirsten Palmer, Laura Tuohey, Louie Ye, Stephen Tong |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3387233?pdf=render |
Similar Items
-
Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction – implications as a preeclampsia treatment
by: Natalie J. Hannan, et al.
Published: (2017-05-01) -
Diagnostic and prognostic significance of serum soluble endoglin levels in preeclampsia and eclampsia
by: Rekha Sachan, et al.
Published: (2016-01-01) -
Structural and Functional Characteristics of a Soluble Form of Endoglin in the Context of Preeclampsia
by: Gregory, Allison
Published: (2011) -
Structural and Functional Characteristics of a Soluble Form of Endoglin in the Context of Preeclampsia
by: Gregory, Allison
Published: (2011) -
Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia.
by: Sarosh Rana, et al.
Published: (2012-01-01)